Market news

* Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements * Gross margins of over 90% \- among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients * Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with

7 million contracted units added in under two weeks \- Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today * Secured orders for 1.

* Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock * Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. * CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption * Intellectual property owned outright, with pat

* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.

Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufac

2 million in adjusted EBITDA and $31 million in net incomeCHICAGO, IL / ACCESS Newswire / September 9, 2026 / ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet.C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) →...

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah Group, whose healthcare arm reports sales exceeding $2 billionInitial purchase order of 126,000 Sky Premium Life units secured on execution of the agreementExclusive rights across Saudi Arabia for an initial five years, spanning pharmacies, retail and online platforms, with potential to renew for a

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 millionContinued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8%Demonstrated operating leverage and disciplined inventory management, with Q2 operat

Digital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own packageCorporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account managementFuture platform enhancements

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) has continued to strengthen its position as a diversified, vertically integrated global healthcare company with operations spanning pharmaceutical manufacturing, nutraceuticals, over-the-counter healthcare products, pharmaceutical distribution, telehealth, and artificial intelligence-driven drug

Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer accessExpansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos He

Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed (NASDAQ:ADVB) shares

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 mi

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to revenue and cash-flow visibilityAs a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reachDIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022Po

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 190,000 shares of its common stock in the open market at an average price of approximately $0.2805 per share. The Company has now repurchased a total of 4,060,000 shares for approximately $811,000 under its previously announced share repurchase program of up to $5 million

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46 million in H1 20253,640,000 shares repurchased as of July 6, 2026 for approximately $700,000 under the Company's $5 million buyback program, with open market purchases ongoing CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ: